Genital Warts Market Growth Anticipated by 2032 | Major Players: Tamir Biotechnology (Orgenesis), Verrica Pharmaceuticals, Novan Inc., expected to boost the market

In the market landscape of Genital Warts, an impressive surge is expected during the study period spanning 2019 to 2032, according to latest report titled  “Genital Warts Market Insights, Epidemiology and Market Forecast 2032” from DelveInsight. 

The increase in market size of Genital Warts is a consequence of expected approval of emerging treatment options in the 7MM.

The Genital Warts market report sheds light on Genital Warts current treatment practices, upcoming drugs in the Genital Warts pipeline, market shares of individual therapies, and the anticipated trajectory of the Genital Warts market size from 2019 to 2032 across the 7MM (the United States, the EU-4 comprising Italy, Spain, France, and Germany, the United Kingdom, and Japan).

Driving Forces Behind the Genital Warts Market Growth

The overall market of Genital Warts is expected to boost due to emerging treatment alternatives. With the expected launch of emerging therapies, the Genital Warts treatment market will increase during the forecast period (2023–2032).

Discover the Anticipated Evolution and Growth of the Market @ Genital Warts Therapeutics Market Forecast

Therapeutic Advancements and Emerging Treatments:

• Genital Warts Clinical Trial Progression: The market is set to experience significant growth, driven by the progression of emerging therapies expected for launch between 2023 and 2032. Pioneering companies, including Tamir Biotechnology (Orgenesis), Verrica Pharmaceuticals, Novan Inc., and others, are actively engaged in developing novel drugs for potential market entry.
• Genital Warts Innovative Therapies: Ongoing research and development activities are fostering the introduction of innovative therapies designed to address the signs and symptoms of Genital Warts. Therapies such as Onconase, VP-102, SB207, and others are driving the Genital Warts market.

Genital Warts Treatment Market

The current therapeutic options available for the treatment of GWs are largely centered upon removal of the warts. There is little evidence to suggest that existing treatments are effective in the long-term eradication of genital warts or that they play any significant role in reducing the relapse rate of disease. A wide range of therapies are presently in use, which are highly variable and can differ dramatically with respect to cost, side-effect profiles, dosing schedules, duration of treatment, and overall effectiveness. 

The DelveInsight’s market forecast focus on the market revenue generated by pharmacological therapies (including all the currently used chemical therapies) prescribed for the management of genital warts and doesn’t comprise the revenue generated by devices &/or surgical procedures (such as Cryotherapy, Electro surgery, Scissor excision or laser removal of warts) or prophylaxis measures (Gardasil or Cervarix). The market is subdivided bases of mode of treatment that is either Topical or Systemic treatment. 

Genital warts (GWs) treatment market is categorized on the basis mode of treatment, Topical treatment (such as Imiquimod (Aldara, Zyclara), Podophyllin and podofilox (Condylox), Sinecatechins (Veregen)), and Systemic treatment (such as Alferon N).

Among topical drugs, Imiquimod (imidazoquinolinamine) 5% cream is a patient-applied topical immunomodulatory agent, which first received its indication for the treatment of external GW by FDA in 1997. Although, the FDA approved the use of a 3.75% formulation of topical Imiquimod cream for the treatment of GWs; as observed in studies primary cure rates for the 3.75% formulation are not as high as the 5% counterpart; however, the newer product is thought to have several considerable benefits with respect to patient compliance.

Another drug Sinecatechins 15% cream (Veregen) is applied topically to warts three times a day for up to four months to treat genital warts. Sinecatechins is a botanical extract approved in 2006 by the United States Food and Drug Administration (FDA) for the treatment of genital warts, making it the first botanical to officially receive medical approval. Sinecatechins 10% & 15% Ointment (Veregen) have been included in the 2012 European Guideline for the Management of Anogenital Warts. 

Yet another topical drug called Podophyllotoxin (also known as Podofilox) (0.05% solution or gel and 0.15% cream) is generally thought to be safe, effective, and can be self-administered. Typically, the solution is recommended for penile lesions, whereas cream or gel vehicle preparations are thought to be more comfortable for application to anal or vaginal lesions. 

Among the systemic treatment use of interferon therapy (such as Alferon N) for the treatment of genital warts remains somewhat debatable. Due to its direct immune-boosting effects, interferon therapy is likely to promote the clearance of underlying virally infected cells in addition to targeting external lesions. This may ultimately lead to lower rates of recurrence and better long-term results, especially when used synergistically with other treatment modalities. Thus Alferon N is usually given after other medications have been tried without successful treatment of genital warts.

Along with mentioned topical therapies, there are a variety of treatment options for genital warts. No data shows the superiority of one treatment over another. 

There is an absence of standardized treatment as all treatment options are associated with risk of recurrence and there is a paucity of patient-applied modalities to directly combat with the existential threats of the invading warts symptoms. The management of genital warts can be very challenging and a substantial burden for patients. Continuous research, with the potential to clear the warts quickly, reduce the pain of treatment, and introduce more of patient-applied therapies to reduce the burden of repeated visits to clinics has paved a way for the leading pharma players to address and bridge the existing gaps in the treatment of warts.

Genital Warts Treatment Market

The FDA-endorsed medications for managing IC patients encompass Elmiron (Janssen Pharmaceutical). Elmiron (Pentosan polysulfate sodium), a low molecular weight compound akin to heparin, is designed for oral administration and stands as the first and sole FDA-sanctioned bladder instillation explicitly developed for Genital Warts.

Bladder instillations involving anesthetic solutions are employed to manage bladder pain, with heparin agents believed to aid in repairing the damaged urothelium. As per the American Urological Association’s practice guideline for Genital Warts, bladder instillations are considered a secondary treatment option when adjustments in diet, stress management, and over-the-counter remedies yield insufficient relief. Various types of instillations currently available in the market encompass Alkalinized Lidocaine and Heparin, DMSO, Sodium Hyaluronate, and BCG.

Genital Warts Market Report Features

Geography Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

Study Period: 2019-2032

Genital Warts Market Size: USD XX million in 2032

Key Genital Warts Companies: Tamir Biotechnology (Orgenesis), Verrica Pharmaceuticals, Novan Inc., and others.

Leading Genital Warts Companies and Emerging Drugs: Pioneering companies such as Tamir Biotechnology (Orgenesis), Verrica Pharmaceuticals, Novan Inc., among others, are actively developing novel drugs for potential entry into the Genital Warts market.

Genital Warts Therapeutic Landscape: Key therapies identified for Genital Warts treatment include Onconase, VP-102, SB207, and more.

Genital Warts Overview:

Genital warts are a sexually transmitted infection (STI) caused by the human papillomavirus (HPV). They appear as small growths or bumps in the genital or anal area. HPV is a common virus, and some strains can cause genital warts, while others can lead to cervical cancer and other cancers.

Symptoms: Genital warts can vary in appearance. They might be flat, raised, small, or clustered in a cauliflower-like shape. They can appear on the penis, vulva, vagina, cervix, anus, or groin area. Sometimes, they cause itching, discomfort, or bleeding during sex.

Transmission: HPV is primarily spread through sexual contact, including vaginal, anal, or oral sex with an infected person. It can also spread through skin-to-skin contact in the genital area, even if there are no visible warts.

Diagnosis: Doctors typically diagnose genital warts by visually inspecting the affected area. In some cases, further tests such as a biopsy may be done to confirm the diagnosis, especially if there are other concerning symptoms.

Treatment: There's no cure for HPV, but treatments can help manage and remove genital warts. These treatments might include topical medications, freezing (cryotherapy), laser therapy, or surgical removal. However, the virus may remain in the body even after wart removal, and warts can reappear.

Prevention: HPV vaccines are available and are highly effective in preventing the types of HPV that cause most cases of genital warts and certain cancers. Safe sex practices, including the use of condoms, can also reduce the risk of HPV transmission.

Key Facts Genital Warts Market Report:

• Key players such as Tamir Biotechnology (Orgenesis), Verrica Pharmaceuticals, Novan Inc., and others are investigating its candidates for Genital Warts.
• Genital Warts pipeline includes the major therapies such as Onconase, VP-102, SB207, and others. 
• As per the assessment by DelveInsight, throughout the study period, females diagnosed with Genital Warts are higher as compared to males. 
• As per the assessment by DelveInsight, throughout the study period, a increasing trend in the incident cases of Genital Warts is expected to occur in the US. 
• As per the assessment by DelveInsight, throughout the study period In the US, incidence of genital warts is the highest among people with age 18-29 years followed by 30 to 39 years and 40 and above years age groups. 

Genital Warts Epidemiology Segmentation:

Based on the literature review on Anatomical locations of Genital Warts for 7MM, it can be concluded that Genital Warts most frequently occur in vulva and cervix

• As per the assessments by DelveInsight, total incident cases of Genital Warts in the 7MM were found to be approximately 868,491 in 2021, which are expected to decrease slightly during the study period (2019-2032).
• Among the 7MM countries, the United States reported approximately 545,316 total incident cases of Genital Warts in 2021, which was equivalent to 63% of the total incident cases in the 7MM.
• In 2021, Japan had 38,043 total incident cases of Genital Warts ranking lowest among the 7MM. These cases are expected to decrease by 2032 at a CAGR of -0.85% during the forecast period (2023–2032).

The Genital Warts market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Genital Warts

• Prevalent Cases of Genital Warts by severity

• Gender-specific Prevalence of Genital Warts

• Type-specific Prevalence of Genital Warts

• Age-specific Prevalence of Genital Warts

• Diagnosed Cases of Genital Warts

DelveInsight's comprehensive report provides a thorough exploration of the Genital Warts market, covering key Genital Warts players, emerging Genital Warts therapies, treatment dynamics, and market challenges.

For in-depth insights, access the full report @ Genital Warts Market Outlook 2032

DelveInsight's report offers comprehensive insights, market analysis, and forecasts aiding leading companies in strategic decision-making for the Genital Warts market landscape.

• Gain Competitive Edge in Indication Market : Understand the current landscape of the Genital Warts market, including the competitive environment, key companies developing drugs for Genital Warts , and their strategies. By analyzing market dynamics, treatment approaches, and emerging therapies, stakeholders can identify opportunities to position themselves effectively, gaining a competitive edge over others.
• Identify Market Gaps and indication market opportunities : Analyzing epidemiological trends, country wise patient journeys and existing tretment practices can helps in identifying gaps and opportunities within the Genital Warts market. This involves recognizing areas where current treatments may be insufficient or where there is an unmet need. The report is curated by taking account of various KOLs dealing with Genital Warts. Identifying these gaps allows stakeholders to explore new therapeutic avenues, potentially leading to the development of novel treatments that address specific market needs and price their emerging products strategically to gain a competitive edge.
• Strategic decision making : Armed with insights from epidemiological and market forecasts, stakeholders can make informed and strategic decisions. This may involve deciding on research and development investments, portfolio expansion, pricing - reimbursement strategies, partnerships, or other strategic moves. Understanding the market dynamics enables stakeholders to align their goals with the prevailing trends and future projections.
• Plan RoadMap to Success : Through this report the leading companies can set short-term and long-term goals, define strategies for market penetration, and outline steps for product development or market expansion. A well-informed roadmap ensures that stakeholders navigate the complexities of the Genital Warts market with clarity and purpose.

Related Reports:

Genital Warts Epidemiology Forecast

Genital Warts Epidemiology Forecast report delivers an in-depth understanding of the Genital Warts, historical and forecasted epidemiology in the United States, the EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Genital Warts Pipeline Insight

Genital Warts Pipeline Insight report provides comprehensive insights about companies and pipeline drugs in the Genital Warts pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. 

Healthcare Consulting and Market Research Services by DelveInsight

Discover how DelveInsight’s comprehensive analysis and proactive strategies facilitated a US-based pharmaceutical client’s triumphant entry into the European biosimilar landscape. Download Pharma Go-to-Market Case Study.

Trending Reports by DelveInsight

Functional Constipation Market

https://www.delveinsight.com/report-store/chronic-constipation-market

Lebers Hereditary Optic Neuropathy Market

https://www.delveinsight.com/report-store/lebers-hereditary-optic-neuropathy-lhon-market

Gastric Neuroendocrine Tumors Market

https://www.delveinsight.com/report-store/gastric-neuroendocrine-tumors-market

Immune Thrombocytopenic Purpura Market

https://www.delveinsight.com/report-store/immune-thrombocytopenia-itp-market

Visceral Pain Associated With GI Disorders Market

https://www.delveinsight.com/report-store/visceral-pain-associated-with-gi-disorders-market

Bullous Pemphigoid Market

https://www.delveinsight.com/report-store/bullous-pemphigoid-market

Cyclin-dependent Kinase-like 5 Deficiency Disorder Market https://www.delveinsight.com/infographics/cyclin-dependent-kinase-like-5-cdkl5-deficiency-disorder-market

Myocarditis Market

https://www.delveinsight.com/report-store/myocarditis-market

Recurrent Blood Clots Market

https://www.delveinsight.com/report-store/recurrent-blood-clots-thrombophilia-market

Zollinger-ellison Syndrome Market

https://www.delveinsight.com/report-store/zollinger-ellison-syndrome-market

Age-related Hearing Loss Medical Device Market

https://www.delveinsight.com/blog/age-related-hearing-loss-device-market

Heart Sounds Sensors Market

https://www.delveinsight.com/report-store/heart-sounds-sensors-electronic-stethoscope-market

Hypoplastic Left Heart Syndrome Hlhs Market

https://www.delveinsight.com/report-store/hypoplastic-left-heart-syndrome-market

Infectious Arthritis/Septic Arthritis Market

https://www.delveinsight.com/report-store/infectious-arthritisseptic-arthritis-market

Plasmacytoma Market

https://www.delveinsight.com/report-store/plasmacytoma-market

Agoraphobia Market

https://www.delveinsight.com/report-store/agoraphobia-market

Clinically Isolated Syndrome CIS Market

https://www.delveinsight.com/report-store/clinically-isolated-syndrome-cis-market

Fucosidosis Market

https://www.delveinsight.com/report-store/fucosidosis-market

Major Depressive Disorder Market

https://www.delveinsight.com/report-store/major-depressive-disorder-market

Neuronal Ceroid-lipofuscinoses Market

https://www.delveinsight.com/report-store/neuronal-ceroid-lipofuscinoses-cln1-disease-market

Orthotic Devices Market

https://www.delveinsight.com/report-store/orthotic-devices-market

About DelveInsight:

DelveInsight is a prominent business consultant and market research firm specializing in the life sciences sector. With a focus on supporting pharmaceutical companies, DelveInsight provides end-to-end solutions to enhance their performance.

Connect with DelveInsight:

LinkedIn | Facebook | Twitter

Contact Us:

Kritika Rehani

Team Lead, Marketing

krehani@delveinsight.com

+91-9650213330

www.delveinsight.com